Lucira Health, Inc. (LHDX)
Chart Events
Performance Outlook
| Previous Close | 9.17 |
| Open | 9.13 |
| Bid | 9.40 x 1000 |
| Ask | 9.54 x 1100 |
| Day's Range | 8.56 - 9.80 |
| 52 Week Range | 4.23 - 37.99 |
| Volume | 546,115 |
| Avg. Volume | 2,408,762 |
| Market Cap | 366.082M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.50 |
- GlobeNewswire
Lucira Health to Announce Second Quarter 2021 Financial Results
EMERYVILLE, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report second quarter 2021 financial results on, Thursday, August 12, 2021. Lucira’s management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and pro
- Motley Fool
2 Under-the-Radar Stocks to Buy Now
COVID-19 testing company Lucira Health became public only in February, but it has been plagued by problems since. Lucira's flagship device is a single-use, do-it-yourself COVID-19 test kit that received regulatory clearance for over-the-counter use in April. Overall, it was a major innovation by Lucira Health, but it came a tad bit too late.
- Motley Fool
5 Stocks to Own for the Surge in Coronavirus Variants
Although the pandemic has mostly faded from the front pages, mutations of the SARS-CoV-2 virus are increasing the odds that COVID will make a resurgence this winter. Add in many Americans' hesitancy over vaccines, and it appears the companies providing testing, treatments, and vaccine boosters could remain a part of our lives longer than it seemed only a few months ago. Revenue rose 1,200% on the back of a 74-fold increase in testing volume.
